Division of Hematology and Oncology

April 20, 2021

New therapeutic strategy for leukemia syndrome

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

By Leigh MacMillan
April 16, 2021

New Clinician Spotlight: Laura Kennedy

Laura Kennedy, MD, PhD, has joined Vanderbilt University Medical Center from the University of Washington School of Medicine/Fred Hutchinson Cancer Research Center in Seattle where she was acting instructor and research associate.

By VUMC News and Communications
Benjamin Brown, left, Jens Meiler, PhD, Zhenfang Du, PhD, and colleagues are studying the functional consequences of genetic mutations and how those changes can drive cancerous growth.
April 8, 2021

Personalized Structural Biology aids cancer treatment decisions

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

By Bill Snyder
April 5, 2021

New Clinician Spotlight: Robert Ramirez

Robert Ramirez, DO, a thoracic and neuroendocrine oncologist, has joined Vanderbilt-Ingram Cancer Center after practicing at Ochsner Medical Center and Louisiana State University (LSU) Health Science Center in New Orleans.

By VUMC News and Communications
March 25, 2021

Effort seeks to enroll more Black patients in lung cancer trials

Researchers from Vanderbilt University Medical Center are part of a multi-institutional study that aims to improve participation in lung cancer clinical trials among Black patients from Southern states.

By Tom Wilemon
March 23, 2021

Prostate cancer microenvironment

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

By Leigh MacMillan
March 18, 2021

EGFR Resisters/LUNGevity fund lung cancer research

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.
By Tom Wilemon
February 25, 2021

Gift in memory of Phran Galante boosts lung cancer research

A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.
By Tom Wilemon
December 22, 2020

Arthritis drug may treat immunotherapy-related heart complication

By Tom Wilemon
November 18, 2020

New drug for metastatic colorectal cancer enters phase 3 trial

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
By Tom Wilemon
November 10, 2020

Study underscores importance of personalized medicine in kidney cancer

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
By Tom Wilemon
October 29, 2020

Rini to lead NCI study of COVID-19 in cancer patients

Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.
By Tom Wilemon
October 29, 2020

Lovly to chair foundation’s scientific leadership board

Christine Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, has been named incoming chair of GO2 Foundation's Scientific Leadership Board (SLB).
By Tom Wilemon
1 … 5 6 7 8 9 … 15